Axsome Therapeutics’ (AXSM) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM) in a research report released on Tuesday morning,Benzinga reports. They currently have a $180.00 price objective on the stock. HC Wainwright also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($0.92) EPS, FY2024 earnings at ($4.58) EPS, Q1 2025 earnings at ($0.85) EPS, Q2 2025 earnings at ($0.59) EPS, Q3 2025 earnings at ($0.31) EPS, Q4 2025 earnings at $0.38 EPS and FY2025 earnings at ($1.37) EPS.

Several other research firms have also recently weighed in on AXSM. Robert W. Baird boosted their target price on Axsome Therapeutics from $112.00 to $116.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Truist Financial upped their target price on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the company a “buy” rating in a report on Monday, January 13th. StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $121.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Finally, Mizuho cut their target price on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating on the stock in a research report on Tuesday, December 31st. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $130.69.

Axsome Therapeutics Trading Up 1.6 %

NASDAQ AXSM opened at $103.89 on Tuesday. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $105.00. The firm has a 50 day moving average of $92.32 and a two-hundred day moving average of $89.80. The company has a quick ratio of 2.37, a current ratio of 2.44 and a debt-to-equity ratio of 1.97. The stock has a market capitalization of $5.03 billion, a PE ratio of -15.91 and a beta of 1.04.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.04. The firm had revenue of $104.76 million during the quarter, compared to the consensus estimate of $98.71 million. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. During the same quarter in the previous year, the firm posted ($1.32) earnings per share. As a group, research analysts expect that Axsome Therapeutics will post -4.73 EPS for the current fiscal year.

Hedge Funds Weigh In On Axsome Therapeutics

Institutional investors have recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Axsome Therapeutics during the 2nd quarter worth approximately $27,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in Axsome Therapeutics in the second quarter worth $47,000. R Squared Ltd acquired a new stake in Axsome Therapeutics in the fourth quarter valued at $64,000. KBC Group NV boosted its position in shares of Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock worth $113,000 after purchasing an additional 385 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock worth $156,000 after purchasing an additional 318 shares during the period. 81.49% of the stock is owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.